310 related articles for article (PubMed ID: 27466943)
1. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
Singhal T; Tauhid S; Hurwitz S; Neema M; Bakshi R
J Neuroimaging; 2017 Jan; 27(1):33-36. PubMed ID: 27466943
[TBL] [Abstract][Full Text] [Related]
2. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
[TBL] [Abstract][Full Text] [Related]
3. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
4. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
[TBL] [Abstract][Full Text] [Related]
5. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
[TBL] [Abstract][Full Text] [Related]
6. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
8. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
10. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
[TBL] [Abstract][Full Text] [Related]
11. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
12. Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
Lundell H; Svolgaard O; Dogonowski AM; Romme Christensen J; Selleberg F; Soelberg Sørensen P; Blinkenberg M; Siebner HR; Garde E
Acta Neurol Scand; 2017 Oct; 136(4):330-337. PubMed ID: 28070886
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
[TBL] [Abstract][Full Text] [Related]
16. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
[TBL] [Abstract][Full Text] [Related]
17. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
[TBL] [Abstract][Full Text] [Related]
18. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
19. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
20. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
